Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Denis Raccah. (2017) Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues. Expert Opinion on Drug Safety 16:2, pages 227-236.
Read now
Read now
D Cimmaruta, MI Maiorino, C Scavone, L Sportiello, F Rossi, D Giugliano, K Esposito & A Capuano. (2016) Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opinion on Drug Safety 15:sup2, pages 77-83.
Read now
Read now
Edoardo Mannucci & Ilaria Dicembrini. (2012) Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion 28:5, pages 715-721.
Read now
Read now
Articles from other publishers (36)
Hsuan-Wen Chou, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu & Horng-Yih Ou. (2022) Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals 15:12, pages 1569.
Crossref
Crossref
Musaab Ahmed, Safaa Badi, Ala Elidrisi, Nazik Elmalaika Husain, Sueziani Binte Zainudin, Arshad Mahmood, Nuha Eljaili Abubaker, Abdullah S. Alghamdi & Mohamed H. Ahmed. (2022) Safety and effectiveness of newer antidiabetic medications during Ramadan fasting and safety of Ramadan fasting after bariatric surgery. Journal of Diabetes & Metabolic Disorders 21:2, pages 1991-2004.
Crossref
Crossref
Artemis Kyriakidou, Angeliki V. Kyriazou, Theocharis Koufakis, Yiannis Vasilopoulos, Maria Grammatiki, Xanthippi Tsekmekidou, Iakovos Avramidis, Stefanos Baltagiannis, Dimitrios G. Goulis, Pantelis Zebekakis & Kalliopi Kotsa. (2022) Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes. Journal of Personalized Medicine 12:3, pages 424.
Crossref
Crossref
Anna A Mosikian, Tatiana I Golikova, Mariia V Martjanova & Alina Y Babenko. (2022) Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes. Future Science OA 8:3.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
199
229
.
Kun Yang, Haining Wang, Rui Wei, Wenhua Xiao, Qing Tian, Chen Wang, Jin Yang & Tianpei Hong. (2021) High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes. Acta Diabetologica 58:5, pages 595-602.
Crossref
Crossref
Xuejun Victor Peng, Rory J. McCrimmon, Leah Shepherd, Anders Boss, Robert Lubwama, Terry Dex, Neil Skolnik, Linong Ji, Angelo Avogaro & Lawrence Blonde. (2020) Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. Diabetes Therapy 11:11, pages 2629-2645.
Crossref
Crossref
A. Yu. Babenko, Yu. A. Kononova, M. V. Martjanova, A. V. Simanenkova, M. A. Kokina & E. V. Shlyachto. (2020) Glucagon-like peptide-1 agonist therapy in patients with diabetes mellitus and obesity. Clinical Medicine (Russian Journal) 98:3, pages 210-217.
Crossref
Crossref
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli & Laura Fumagalli. (2020) Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules 25:8, pages 1987.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya, Gagan Priya, Manoj Chawla, Kiraninder Brar, Syed Abbas Raza, Azizul Hasan Aamir, Dina Shrestha, Noel Somasundaram, Prasad Katulanda, Faria Afsana, Shahjada Selim, Mohammad Wali Naseri, Ali Latheef & Manilka Sumanatilleke. (2019) Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Therapy 10:5, pages 1645-1717.
Crossref
Crossref
Hakan Dogruel & Mustafa Kemal Balci. (2019) Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future. World Journal of Diabetes 10:8, pages 446-453.
Crossref
Crossref
Alina Yu. Babenko, Daria A. Savitskaya, Yulia A. Kononova, Aleksandra Yu. Trofimova, Anna V. Simanenkova, Elena Yu. Vasilyeva & Evgeny V. Shlyakhto. (2019) Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity. Journal of Diabetes Research 2019, pages 1-12.
Crossref
Crossref
Miriam Longo, Giuseppe Bellastella, Maria Ida Maiorino, Juris J. Meier, Katherine Esposito & Dario Giugliano. (2019) Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Frontiers in Endocrinology 10.
Crossref
Crossref
Sara J. Brandt, Anna Götz, Matthias H. Tschöp & Timo D. Müller. (2018) Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100, pages 190-201.
Crossref
Crossref
Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A. Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis & Christos S. Mantzoros. (2018) Pharmacotherapy of type 2 diabetes: An update. Metabolism 78, pages 13-42.
Crossref
Crossref
David R. Owens, Louis Monnier & Anthony H. Barnett. (2017) Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. Diabetes, Obesity and Metabolism 19:10, pages 1339-1352.
Crossref
Crossref
Silvia Beatriz Gorban de Lapertosa, Gustavo Frechtel, Elise Hardy & Leobardo Sauque-Reyna. (2016) The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial. Diabetes Research and Clinical Practice 122, pages 38-45.
Crossref
Crossref
Hua Shu, Li-na Gu, Li-chuang Men & Ju-ming Lu. (2016) Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis. Diabetes Therapy 7:4, pages 777-792.
Crossref
Crossref
Eun Ju Lee & Tae Nyun Kim. (2016) Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. The Korean Journal of Obesity 25:3, pages 121-128.
Crossref
Crossref
Marcus Lind, Per-Olov Matsson, Ragnar Linder, Irene Svenningsson, Leif Jørgensen, Uffe J. Ploug, Helge Gydesen, Mozhgan Dorkhan, Sara Larsen & Gunnar Johansson. (2016) Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden. Diabetes Therapy 7:2, pages 321-333.
Crossref
Crossref
Lin Zhang, Mei Zhang, Yuwei Zhang & Nanwei Tong. (2016) Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Scientific Reports 6:1.
Crossref
Crossref
Jessica E. Potts, Laura J. Gray, Emer M. Brady, Kamlesh Khunti, Melanie J. Davies & Danielle H. Bodicoat. (2015) The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLOS ONE 10:6, pages e0126769.
Crossref
Crossref
Luc Van Gaal & André Scheen. (2015) Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care 38:6, pages 1161-1172.
Crossref
Crossref
Jia Liu, Guang Wang, Yumei Jia & Yuan Xu. (2015) GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes/Metabolism Research and Reviews 31:4, pages 329-335.
Crossref
Crossref
Denis Raccah, Pierre Gourdy, Luc Sagnard & Antonio Ceriello. (2014) Lixisenatide as add‐on to oral anti‐diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. Diabetes/Metabolism Research and Reviews 30:8, pages 742-748.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, K. S. Park & Y. M. Cho. (2014) Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 16:10, pages 900-909.
Crossref
Crossref
Zachary T Bloomgarden. (2014) Basal insulin or longacting GLP-1 receptor agonists—making the right choice. The Lancet Diabetes & Endocrinology 2:6, pages 439-441.
Crossref
Crossref
Miguel Camafort-Babkowski. (2013) Impacto del tratamiento antidiabético con fármacos agonistas del receptor de péptido de tipo 1 similar al glucagón en el riesgo cardiovascular de pacientes con diabetes mellitus tipo 2. Medicina Clínica 141:4, pages 167-174.
Crossref
Crossref
Robert R. Henry, Douglas Logan, Thomas Alessi & Michelle A. Baron. (2013) A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.. Clinical Therapeutics 35:5, pages 634-645.e1.
Crossref
Crossref
Young Min ChoRhonda D. WidemanTimothy J. Kieffer. (2013) Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. Endocrinology and Metabolism 28:4, pages 262.
Crossref
Crossref
K. Fosgerau, L. Jessen, J. Lind Tolborg, T. Østerlund, K. Schaeffer Larsen, K. Rolsted, M. Brorson, J. Jelsing & T. Skovlund Ryge Neerup. (2013) The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diabetes, Obesity and Metabolism 15:1, pages 62-71.
Crossref
Crossref
A. R. Meloni, M. B. DeYoung, C. Lowe & D. G. Parkes. (2012)
GLP
‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence
. Diabetes, Obesity and Metabolism 15:1, pages 15-27.
Crossref
Crossref
Jeffrey S. Freeman. (2013) Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. Osteopathic Family Physician 5:1, pages 43-50.
Crossref
Crossref
S. Paul, J. Best, K. Klein, J. Han & D. Maggs. (2012)
Effects of HbA
1c
and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide
*
. Diabetes, Obesity and Metabolism 14:9, pages 826-834.
Crossref
Crossref
Vanita R. Aroda, Robert R. Henry, Jenny Han, Wenying Huang, Mary Beth DeYoung, Tamara Darsow & Byron J. Hoogwerf. (2012) Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 34:6, pages 1247-1258.e22.
Crossref
Crossref